Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T

Magnetic Resonance in Medicine

Volumn 62, Issue 4, 2009, Pages 855-861

  McLean, Mary A ^a   Priest, Andrew N ^b,c   Joubert, Ilse ^c   Lomas, David J ^c   Kataoka, Masako Y ^c   Earl, Helena ^d   Crawford, Robin ^b   Brenton, James D ^e   Griffiths, John R ^a   Sala, Evis ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Li Ka Shing Centre   (United Kingdom)

Author keywords

Choline; Glycine; Magnetic resonance spectroscopy; Metastatic disease; Ovarian cancer

Indexed keywords

AMINO ACIDS; DISEASES; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; METABOLITES;

BENIGN LESION; CHOLINE; FALSE NEGATIVES; METABOLITE CONCENTRATIONS; METASTATIC DISEASE; METASTATIC LESIONS; OVARIAN CANCERS; STANDARD DEVIATION;

SIGNAL TO NOISE RATIO;

CHOLINE; GLYCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE QUALITY; IN VIVO STUDY; METABOLITE; OVARY CANCER; OVARY METASTASIS; PRIMARY TUMOR; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 70349613202     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22067     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-1559.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
4. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516. (Pubitemid 37328838)
5. Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993;186:745-752. (Pubitemid 23073517)
6. Tate AR, Underwood J, Acosta DM, Julià-Sapé M, Majó s C, Moreno- Torres A, Loosemore A, Ladroue C, Wesseling P, Bosson JL, Cabanas ME, Simonetti AW, Gajewicz W, Calvar J, Capdevila A, Wilkins PR, Bell BA, Rémy C, Heerschap A, Watson D, Griffiths JR, Arus C. Development of a decision support system for diagnosis and grading of brain tumours using in vivo single voxel magnetic resonance spectra. NMR Biomed 2006;19:411-434.
7. Huzjan R, Sala E, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol 2005;2:434-442. (Pubitemid 41486125)
8. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 1998;206:785-790. (Pubitemid 28128531)
9. Hascalik S, Celik O, Sarac K, Meydanli MM, Alkan A, Mizrak B. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest 2005;60:121-127. (Pubitemid 41433922)
10. Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging 2001;13:912-917. (Pubitemid 32479950)
11. Pickles MD, Booth SJ, Balan P, Siddons DJ, Manton DJ, Lowry M, Turnbull LW. Single voxel in vivo proton spectroscopy of gynaecology lesions: initial experiences of choline quantification at 1.5T and 3.0T. In: Proc 15th Annual Meeting ISMRM, Berlin; 2007:2861.
12. Stanwell P, Russell P, Carter J, Pather S, Heintze S, Mountford C. Evaluation of ovarian tumours by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol 2008;43:745-751.
13. Booth SJ, Pickles MD, Turnbull LW. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG 2009;116:300-303.
14. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005;65:9369-9376. (Pubitemid 41508005)
15. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
16. Haddadin IS, McIntosh A, Meisamy S, Corum C, Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 2009;22:65-76.
17. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000;43: 23-33. (Pubitemid 30027109)
18. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321. (Pubitemid 27328261)
19. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998;11: 266:272. (Pubitemid 28465190)
20. Edden RA, Schar M, Hillis AE, Barker PB. Optimized detection of lactate at high fields using inner volume saturation. Magn Reson Med 2006;56:912-917. (Pubitemid 44477675)
21. Merkle EM, Dale BM. Abdominal MRI at 3.0 Tesla: the basics revisited. Am J Radiol 2006;186:1524-1532. (Pubitemid 46112514)
22. Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, deSouza NM. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 2007;188:91-98. (Pubitemid 46012494)
23. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
24. Baik H-M, Su M-Y, Yu H, Mehta R, Nalcioglu O. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5T. Magn Reson Mater Phys 2006;19:96-104.
25. Massuger LF, van Vierzen PB, Engelke U, Heerschap A, Wevers R. 1H-magnetic resonance spectroscopy: a new technique to discriminate benign from malignant ovarian tumors. Cancer 1998;82:1726-1730. (Pubitemid 28208924)
26. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC. Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningioma? Neurosurgery 2007;61:1048-1059.
27. Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumours: a 1H NMR spectroscopic investigation. NMR Biomed 2005;18:371-382. (Pubitemid 41410357)
28. Hascalik S, Celik O, Sarac K, Alkan A, Mizrak B. Clinical significance of N-acetyl-L-aspartate resonance in ovarian mucinous cystadenoma. Int J Gynecol Cancer 2006;16:423-427.
29. Boss EA, Moolenaar SH, Massuger LF, Boonsra H, Engelke UF, de Jong JG, Wevers RA. High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed 2000;13:297-305. (Pubitemid 30663793)
30. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo. Am J Physiol 1999;276:E977-E989.
31. Thompson RB, Allen PS. Sources of variability in the response of coupled spins to the PRESS sequence and their potential impact on metabolite quantification. Magn Reson Med 1999;41:1162-1169.